[{"orgOrder":0,"company":"RVAC Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"RVM-V001","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"RVAC Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"RVAC Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"RVAC Medicines \/ Inapplicable"},{"orgOrder":0,"company":"RVAC Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"RVM-V001","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"RVAC Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"RVAC Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"RVAC Medicines \/ Inapplicable"},{"orgOrder":0,"company":"RVAC Medicines","sponsor":"Pavilion Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Series B Financing","leadProduct":"mRNA COVID Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"RVAC Medicines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RVAC Medicines \/ Pavilion Capital","highestDevelopmentStatusID":"4","companyTruncated":"RVAC Medicines \/ Pavilion Capital"}]

Find Clinical Drug Pipeline Developments & Deals by RVAC Medicines

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          STLE Annual Meeting
                          Not Confirmed
                          STLE Annual Meeting
                          Not Confirmed

                          Details : RVM-V001 is a mRNA-based COVID-19 vaccine candidate for which the company has secured approval from the HSA to initiate Phase 1B clinical trial in Singapore to evaluate product's safety and immunogenicity.

                          Product Name : RVM-V001

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          February 20, 2023

                          Lead Product(s) : RVM-V001

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          STLE Annual Meeting
                          Not Confirmed
                          STLE Annual Meeting
                          Not Confirmed

                          Details : Phase 1 study to evaluate the safety, tolerability, and immunogenicity of RVM-V001 administered as a single IM injection in healthy adults. Three dose levels will be evaluated, with progression from low- to high-dose level based on the assessment of safe...

                          Product Name : RVM-V001

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          September 21, 2022

                          Lead Product(s) : RVM-V001

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          STLE Annual Meeting
                          Not Confirmed
                          STLE Annual Meeting
                          Not Confirmed

                          Details : Proceeds from this will be used for preclinical and clinical development of the mRNA vaccine and therapeutics programs and building world class R&D centers and manufacturing capabilities, including R&D center in Singapore and manufacturing facilities in ...

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          April 26, 2022

                          Lead Product(s) : mRNA COVID Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Pavilion Capital

                          Deal Size : $140.0 million

                          Deal Type : Series B Financing

                          blank